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Introduction: Diagnosing the etiology of a rapidly progressive glomerulonephritis is of vital
importance to guide appropriate therapeutic management. This case highlights the complexity
involved in establishing diagnosis when presentation is atypical. In certain cases diagnosis cannot be established based on clinical presentation or biopsy findings alone, and critical analysis
of biopsy findings in context of clinical presentation is crucial to guide the clinical decisionmaking process.
Case presentation: A 47-year-old Hispanic male with history of granulomatosis with
polyangiitis (GPA) in remission on azathioprine, presented with fatigue and lethargy. Physical
examination was unremarkable. Laboratory data revealed elevated creatinine and otherwise
normal electrolytes. Urinalysis showed numerous dysmorphic red blood cells with few red cell
casts. His serologic results were all negative except anti-proteinase-3 antibody at very low titers.
Kidney biopsy showed necrotizing crescentic glomerulonephritis with linear immunoglobulin
G staining along the basement membrane.
Conclusion: This case presented conflicting serologic and histopathologic findings. The presence of anti-proteinase-3 antibody supported diagnosis of recurrence of GPA. However, linear
staining of immunoglobulin G (IgG) on immunofluorescence (IF) staining of renal biopsy supported anti-glomerular basement membrane (GBM) disease. The treatment of anti-GBM disease
and GPA both involve immunosuppression with prednisone and cyclophosphamide. However,
patients with anti-GBM disease are also treated with plasmapheresis early in the disease presentation to prevent further damage. The patient with GPA, on the other hand, was shown to
benefit from plasmapheresis only in the case of severe renal disease (serum creatinine level more
than 5 mg/dL) or pulmonary hemorrhage. In this case, since the patient did not have detectable
circulating anti-GBM antibody, the decision was made not to proceed with plasmapheresis. The
patient was treated with a standard immunosuppressive regimen consisting of prednisone and
cyclophosphamide with partial renal recovery at 2 months.
Keywords: Necrotizing RPGN, Anti-GBM disease, GPA, ANCA - associated vasculitis, dual
antibody-positive disease
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Acute worsening of kidney function associated with glomerular hematuria, as evidenced
by red cell casts or dysmorphic red blood cells, points towards glomerulonephritis.
Glomerulonephritis causing progressive loss of renal function over a relative short
period of time is called rapidly progressive glomerulonephritis (RPGN).1 Several serologic studies may help in evaluating potential cause of glomerulonephritis. However,
kidney biopsy is essential to provide histologic confirmation of the diagnosis. To
clinician’s surprise, coexisting pathologies can often be found on kidney biopsy. In a
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patient with known glomerulonephritis that has responded
well to treatment and has been in remission, recurrent disease would be the most likely etiology of worsening renal
function with glomerular hematuria. Nevertheless, a second
glomerular disease may coexist on kidney biopsy. Therefore,
it is very important to establish a diagnosis before treatment
decisions are made.
Among various causes of RPGN, granulomatosis with
polyangiitis (GPA) (formerly known as Wegener’s granulomatosis) and anti-glomerular basement membrane (GBM)
disease (anti - GBM disease) are two disease processes very
difficult to differentiate clinically due to similar presentation. Wegener’s granulomatosis was renamed as GPA during
the 2012 International Chapel Hill Consensus Conference
that provided revised nomenclature and definitions of vasculitides.2 GPA is a small vessel vasculitis characterized
by granuloma formation and immune deposits of affected
vasculature.3 GPA is part of a spectrum of diseases known
as anti-neutrophil cytoplasmic antibody (ANCA)-associated
vasculitides (AAV), which includes GPA, microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis
(EGPA; formerly known as Churg–Strauss syndrome), and
renal limited vasculitis.3,4
Clinically, three major organ systems are affected in
patients with GPA – ear, nose and throat; respiratory system;
and kidneys. However, not all patients will have all of the
manifestations, and it is not uncommon for AAV to have renallimited presentation. Classically described anti-GBM disease
by Dr Goodpasture (thereby called Goodpasture’s disease)
involves lungs and kidneys.5 However, glomerulonephritis
caused by anti-GBM disease without pulmonary involvement
is also well described.5 Therefore, establishing diagnosis by
clinical presentation alone may be challenging.
Even though serologic tests are not required for diagnosis
of GPA, they are very useful in clinical practice. Circulating
ANCA is positive in approximately 92% of patients with
active GPA,6 whereas, anti-GBM disease is characterized
by antibodies directed against an antigen present in the
GBM.5,6 Presence of circulating anti-GBM antibodies is
crucial for diagnosis of anti-GBM disease. But the serologic
tests by themselves do not establish the diagnosis. Hence,
kidney biopsy findings play a crucial role in establishing
the diagnosis.
The hallmark of renal biopsy findings in patients with GPA
is few or no immune deposits as seen by immunofluorescence
(IF) and electron microscopy.4 Therefore, renal involvement
in GPA is classically described as pauci-immune crescentic
glomerulonephritis (PICGN). Consequently, the finding of
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immune deposits on kidney biopsy points towards separate
etiology. On the other hand, the pathognomonic finding of
anti-GBM disease is linear staining of immunoglobulin (Ig)
G (rarely IgA or IgM) along the basement membrane of
glomerular capillaries on IF staining.7
The diagnostic challenge arises when clinical presentation and serologic tests point towards one disease, but the
biopsy findings support an alternative diagnosis. Since the
treatment of these two disease (GPA and anti-GBM) involves
chemotherapeutic agents (see discussion), one needs to be
very cautious in clinical decision-making. Here we present a
case of conflicting serology and pathology findings.

Case presentation
A 47-year-old Hispanic male presented with lower back
pain, and lethargy. The symptoms started approximately 1
week before presentation. The patient denied having any
upper respiratory symptoms, rash, or joint pain. The patient
also denied having any gross hematuria, foamy urine, or any
other urinary symptoms. The patient’s history included GPA,
diagnosed by a renal biopsy 2 years ago, diabetes mellitus,
hypertension, hyperlipidemia, and diverticulosis requiring
colostomy.
His medication at the time included simvastatin, lisinopril,
azathioprine, and insulin. His azathioprine was reduced from
200 mg/day to 100 mg/day 6 months before presentation. He
had recently lost his job and insurance, and denied smoking,
alcohol use, or any substance abuse. On physical examination, he was afebrile. His blood pressure was 99/51 mmHg,
pulse was 74 beats/minute, and respiration rate 18 breaths/
minute, height was 165 cm, and weight was 97 kg. He was
in no apparent distress. The patient’s lungs were clear, heart
sounds were regular without any murmur, rub, or gallop, the
abdomen was soft, and no edema or skin rash was present.
Laboratory data revealed the patient’s blood urea nitrogen
(BUN) to be 73 mg/dL and serum creatinine (Scr) 5.2 mg/dL
with otherwise normal electrolytes, hemoglobin 12.7 mg/dL,
platelets 257,000/mm3, albumin 3.5 mg/dL, and normal liver
enzymes. Two years prior to current presentation his Scr level
was 1.5 mg/dl. Urinalysis showed large protein, large blood,
many dysmorphic red blood cells and red blood cell casts.
The urine protein to creatinine ratio was 2.03 mg/mg. Renal
sonogram revealed kidney sizes of 11.3 cm and 10.6 cm on
right and left kidneys, respectively, without any evidence of
obstruction and an unremarkable bladder with no significant
postvoid residual volume.
The patient was star ted on high dose pulse
methylprednisolone intravenously (1 g/day for 3 days), and
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his azathioprine dose was increased to 200 mg/day. His
serology showed normal complement titers, negative hepatitis
profile, and mildly elevated rheumatoid factor at 24 IU/ml
(normal ,14). ANCA serology showed proteinase-3 (PR3)
antibody (anti-PR3, cytoplasmic c-ANCA) reactive at
low levels −4.1 (,1.0 reported as negative) and negative
myeloperoxidase (MPO) antibody (anti-MPO, perinuclear
p-ANCA). Anti-GBM titers were negative.
Based on clinical presentation and the patient’s past
medical history, it was presumed that the most likely cause
of worsening renal function was a relapse of GPA. However,
very low levels of anti-PR3 antibodies, and the questionable
duration of the progression of the patient’s renal disease
prompted the nephrology team to proceed with a repeat
kidney biopsy.
The kidney biopsy showed focal segmental necrotizing and crescentic glomerulonephritis, with weak linear
staining of IgG, which was not seen on previous biopsy. Out
of 19 glomeruli examined, nine showed complete or near
complete global sclerosis. Crescents were seen in eleven of
19 glomeruli. The other biopsy findings included moderate
tubular atrophy, moderate interstitial fibrosis with inflammation, and moderate arteriosclerosis (Figures 1 and 2).
The pathologist reported findings suggestive of moderate disease activity and moderate chronicity. Although
the biopsy indicated some evidence of chronic disease,
there was still significant active disease that should be
treated. Provided that the disease process responded to the

Figure 1 Renal biopsy – light microscopy.
Notes: Light microscopic examination of renal biopsy: (A) trichrome stain showing
moderate tubular atrophy, interstitial fibrosis and interstitial inflammation (affecting
50% of cortical area). No interstitial granulomas are seen. (B) Hematoxylin and eosin
stain of glomeruli showing glomerular crescent. (C) Trichrome stain of glomeruli
showing necrotizing crescent. Out of 19 glomeruli examined, nine showed complete
or near complete global sclerosis.
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Figure 2 Renal biopsy – immunofluorescence microscopy.
Notes: Immunofluorescence microscopy of renal biopsy (A and B): Immuno
fluorescence (IF) staining shows weak linear staining of glomerular basement
membranes for IgG. Area of non-staining in figure B represents crescent. The IF was
also positive for kappa and lambda light chains (not shown). Segmental glomerular
tuft staining for IgM, C3, and fibrinogen were also positive (not shown). The
linear staining for IgG was not seen in the previous kidney biopsy and suggests
the possibility of coexistent pauci-immune glomerulonephritis and anti-glomerular
basement membrane nephritis.

t reatment, there was a possibility of at least partial recovery
of renal function.
The biopsy findings presented a treatment dilemma.
The patient had a history of GPA and initially presented
with PICGN and crescentic glomerulonephritis with negative IF findings 2 years previously (Figure 3). At that time,
he was treated with pulse methylprednisolone followed by

Figure 3 Kidney biopsy from 3 years pre-presentation – light microscopy.
Notes: Light microscopy of kidney biopsy. (A) Hematoxylin and eosin (H&E)
stain of glomeruli showing cellular crescent. (B) H&E stain of another glomeruli
showing cellular crescent. (C) Trichrome staining of glomeruli showing necrosis
(red). (D) Trichrome staining of another glomeruli, showing necrosis (red).
(E) Trichrome staining showing moderate tubular atrophy and interstitial fibrosis.
Immunofluorescence staining was negative (not shown). Electron microscopy
revealed 30% foot process effacement but no immune type electron dense deposits
or endothelial tubuloreticular inclusions (not shown).
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6 months of oral prednisone and cyclophosphamide, which
successfully induced remission. His renal function had
improved; Scr decreased from 3.1 mg/dL to 1.5 mg/dL and
proteinuria decreased from 2.3 g/day to ,500 mg/day. He
was then switched to maintenance immunosuppression with
azathioprine. At the time of his initial presentation, his antiPR3 level was .100 U/ml. After initial induction therapy,
anti-PR3 level was reduced below assay limits and remained
negative during follow up.
This patient was treated with pulse dose of intravenous methyl prednisolone 1 g/day for 3 days followed
by maintenance oral prednisone at 1 mg/kg/day. He was
also treated with monthly intravenous cyclophosphamide
(15 mg/kg). Three months later, the patient had partially
responded with proteinuria decreasing to 800 mg/day and
Cr stabilizing to 2.8 mg/dL.

Discussion
This patient presented with elevated BUN and Scr, along
with hematuria and proteinuria. The presence of dysmorphic
red blood cells and red blood cell casts in urine indicate that
hematuria is of glomerular origin. These findings are consistent with the diagnosis of glomerulonephritis. The duration
of the injury in this case is unknown, therefore a chronic
glomerulonephritis as an etiology cannot be ruled out. The
patient may have had disease activity of several months duration, which may have developed extensive fibrotic disease that
may not be treatable with aggressive medical management.
The diagnosis, therefore, requires kidney biopsy to establish
the etiology, as well as to provide prognostic information
regarding the potential of renal recovery with appropriate
treatment. Based on clinical presentation and biopsy findings,
two disease processes need to be considered in differential;
GPA and anti-GBM disease.
Diagnosis of GPA is established if two or more of the
following criteria are met: nasal or oral inflammation; chest
radiograph demonstrating abnormalities such as nodules,
fixed infiltrates, or cavities; abnormal urinary sediment showing microscopic hematuria with or without red blood cell cast;
and arterial or periarteriolar granulomatous inflammation on
biopsy. Diagnosis of anti-GBM disease is based on serologic
and kidney biopsy findings.
Serologic tests can help differentiate between GPA and
anti-GBM disease. In case of GPA, serologic tests for ANCA
are positive in 92% of patients.5 The two major ANCA responsible for clinical disease and systemic vasculitis are directed
against proteinase-3 (PR3) and myeloperoxidase (MPO). To
detect circulating ANCA, there are two main types of assays
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used in clinical practices, indirect immunofluorescence (IF)
assay or enzyme-linked immunosorbent assay (ELISA). 6
The IF technique detects the pattern of staining of antibodies
against human neutrophils, which can be described as diffuse
c-ANCA pattern or p-ANCA pattern.6 C-ANCA pattern is
primarily associated with PR3-ANCA and P-ANCA pattern is largely associated with MPO-ANCA. Occasionally,
PR3-ANCA will demonstrate perinuclear pattern, and MPOANCA may be associated with cytoplasmic pattern on IF.6 The
ELISAs on the other hand, are directed specifically against
PR3 or MPO.8 The IF technique is more sensitive while ELISAs are more specific.8 Laboratory testing for ANCA is not
standardized and therefore the diagnostic ability and reference
values vary among different laboratories using different assay
methods.5 The ANCA in patients with GPA is largely PR3ANCA, but 20% of patients may have MPO-ANCA and up
to 10% of patients may be ANCA negative.9
Anti-GBM antibodies can be detected by either
commercially available ELISA or indirect IF assays. Indirect
IF requires an experienced pathologist to perform and interpret the test, which has a very high false-negative rate, and
is therefore not commercially available.10 ELISA, on the
other hand, is easy to perform but may still be false-negative
in patients with very low titers of anti-GBM antibody.11
Circulating anti-GBM antibodies are not detected by
commercially available ELISAs in the minority of patients
with anti-GBM disease. However, linear deposits of IgG
along the GBM is seen by routine IF microscopy.12 Similarly,
circulating ANCA is present in patients with anti-GBM
disease in up to 33% of patients, with the majority being
anti-MPO antibodies.13 It has also been suggested that antiMPO and anti-PR3 antibodies may disrupt the GBM and
expose the target epitopes involved in pathogenesis of antiGBM disease.14
Histologically, renal biopsy findings in patients with
GPA may range from a mild glomerulonephritis involving
focal and segmental areas, to a diffuse crescentic and necrotizing glomerulonephritis. The hallmark of renal biopsy
findings in patients with GPA is few or no immune deposits
as seen by IF and electron microscopy.3 Therefore, renal
involvement in GPA is classically described as PICGN.
In anti-GBM disease, the kidney biopsy shows crescentic
glomerulonephritis on light microscopy. The pathognomonic finding of anti-GBM disease is linear staining of
IgG (rarely IgA or IgM) along the basement membrane of
glomerular capillaries on IF staining.15 The antibodies are
typically directed against the noncollagenous domain 1
(NC1) of the α-3 chain of type IV collagen.16 The antibody is
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typically IgG (subtypes IgG1 and IgG3) but can sometimes
have IgA or IgM.16
Treatment of GPA includes immunosuppression with
cyclophosphamide and steroids.17 The alternative treatment
with rituximab is also equally effective.18,19 In patients with
GPA presenting with severe renal dysfunction or pulmonary
hemorrhage, plasmapheresis has shown to improve the
outcomes, and lower the risk of end stage renal disease and
death.20 Treatment of anti-GBM disease is directed against
anti-GBM antibody and it consists of plasmapheresis to
remove already existing antibody and other inflammatory
mediators such as cytokines to reduce ongoing damage to
the glomerular and pulmonary basement membranes.21 The
second treatment strategy is to reduce formation of new antiGBM antibodies by means of systemic immunosuppression,
which typically comprises of prednisone and cyclophosphamide.21 It is very important to diagnose anti-GBM disease
early and start treatment as soon as possible. Patients with
more advanced disease presentation, with Scr  5 mg/dL,
are less likely to respond to treatment with almost all patient
(approximately 92%) progressing to end-stage renal disease.
Treatment with plasmapheresis is continued until titer of
anti-GBM is negative. Immunosuppressive regimen typically
continues for 2 to 3 months and then tapers off.22
There are case reports and case series describing patients
with coexisting clinical diseases of anti-GBM antibody and
AAV.23,24 In one such large case series, Levy et al found that
patients with double-positive disease were significantly older
compared to patients with isolated anti-GBM disease.22
Patients with double-antibody positive disease often presented with advanced renal failure, with 70% of patients
requiring immediate renal replacement therapy compared
with 55% of patients with isolated anti-GBM disease. Also,
recovery of renal function despite appropriate immunosuppression and plasma exchange is rare. Also, recovery of
renal function despite appropriate immunosuppression and
plasma exchange is rare in patients with double-antibody
positive disease.22 Approximately 75% of patients presenting
with ANCA disease and severe renal failure requiring renal
replacement therapy, tended to recover renal function with
adequate treatment with immunosuppressive medications,
whereas patients with anti-GBM disease are less likely to
recover renal function (approximately 8%) if presenting
with advanced renal failure.22 Thus, clinical progression of
patients with double-antibody positive disease is worse than
AAV, but similar to anti-GBM disease.
This case presented significant challenges in diagnostic
and therapeutic approaches. Even though the patient had a
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history of GPA, and recurrence was most likely, GPA does
not cause linear IgG deposition on basement membranes.
The patient’s anti-PR3 level, although positive, was very low
compared to his prior presentation. Also, linear IgG staining
presented the possibility of the presence of anti-GBM disease.
However, serologic test for the anti-GBM antibody using
ELISA testing was negative. To our knowledge, this finding
has not been reported in literature.
It is unclear whether there is any direct correlation
between ANCA and anti-GBM antibodies. However,
retrospective studies have demonstrated that in some cases,
development of ANCA antibodies precede development of
anti-GBM antibodies, years to decades before the onset of
clinical disease.25 The anti-GBM antibody was demonstrated
at low-level titers in these patients for years with rapidly rising
titers shortly before development of clinical disease.25 The
mechanism by which ANCA may lead to anti-GBM disease
is unclear but may be associated with ANCA induced damage to the GBM.25
The treatment decision in this patient had to be based on
clinical presentation, which was consistent with GPA given the
prior history and positive anti-PR3 antibody. Since the patient
did not present with any pulmonary hemorrhage and his renal
disease was not very severe (serum Cr level ,5 mg/dL),
this patient would not likely benefit from plasmapheresis
for treatment of GPA. If we were to consider treating the
anti-GBM disease based on his renal histopathology, the
treatment with plasmapheresis may be indicated. However,
the duration of plasmapheresis, as well as treatment response
in the case of anti-GBM is followed by anti-GBM antibody
titer. In our case the titer was negative, as detected by available
commercial assay. Therefore, it would have been difficult to
follow the treatment response and determine the duration of
plasmapheresis. Therefore, the decision was made to proceed
with immunosuppression with prednisone and cyclophosphamide and not to proceed with plasmapheresis. He had partial
response with Scr stabilized at 2.8 mg/dL and proteinuria
decreased to 800 mg/day, 3 months later.

Conclusion
The diagnosis of glomerulonephritis is not always straightforward and requires careful interpretation of clinical, serologic,
and pathologic findings. The treatment of glomerulonephritis
often includes immunosuppression and may even require
plasmapheresis. Clinical decision-making therefore should
be made based on risk-benefit analysis of potential treatment
options. This case presents a clinical dilemma challenged
with conflicting serologic and histopathologic findings.
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